Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd ...

Teva Pharmaceutical Industries Ltd (TEVA) stock saw a decline, ending the day at $21.49 which represents a decrease of $-0.11 or -0.51% from the prior close of $21.6. The stock opened at $21.59 and ...

We recently compiled a list of the 10 Firms End Trading Week Defying Market Bloodbath. In this article, we are going to take ...

Argus has recently raised Teva Pharmaceutical Industries Ltd (TEVA) stock to Buy rating, as announced on July 10, 2024, according to Finviz. Earlier, on March 8, 2024, JP Morgan had raised the stock ...

TEV-56278 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Solid Tumor.

In its survey of the Internet sector, Cantor Fitzgerald selected Wix, led by CEO Avishai Abrahami, as a top pick, along with ...

BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement ...

NYSE:TEVA opened at $22.62 on Friday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $10.39 and a ...

Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...

TEV-56192 is under clinical development by Teva Pharmaceutical Industries and currently in Phase I for Unspecified Neurologic Disorders.

EST Catalyst Pharmaceuticals (CPRX) reports settlement of Firdapse patent litigation with Teva (TEVA) Stay Ahead of the Market:Discover ...

In this article, we are going to take a look at where Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stands against the other stocks. A wave of selling gripped Wall Street this Friday, pushing ...